INBX
NASDAQInhibrx Biosciences Inc.
SectorHealth CareIndustryBiotechnology: Biological Products (No Diagnostic Substances)
Price$123.14+18.43 (+17.60%)
01:30 PM07:45 PM
News · 26 weeks33+200%
2026-03-012026-08-23
Mix1590d
- SEC Filings5(33%)
- Other5(33%)
- Insider4(27%)
- Analyst1(7%)
Latest news
25 items- ANALYSTH.C. Wainwright initiated coverage on Inhibrx Biosciences with a new price targetH.C. Wainwright initiated coverage of Inhibrx Biosciences with a rating of Buy and set a new price target of $245.00
- SECAmendment: SEC Form SCHEDULE 13G/A filed by Inhibrx Biosciences Inc.SCHEDULE 13G/A - Inhibrx Biosciences, Inc. (0002007919) (Subject)
- SECInhibrx Biosciences Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits8-K - Inhibrx Biosciences, Inc. (0002007919) (Filer)
- PRInhibrx Reports Second Quarter 2026 Financial ResultsSAN DIEGO, Aug. 13, 2026 /PRNewswire/ -- Inhibrx Biosciences, Inc. (NASDAQ:INBX) ("Inhibrx" or the "Company") today reported financial results for the second quarter of 2026. The biopharmaceutical company has two programs in ongoing clinical trials. Recent Corporate Highlights and Upcoming MilestonesOxford Loan Amendment. In July 2026, the Company entered into a second amendment to the Loan and Security Agreement (Second Amendment) with Oxford Finance LLC (Oxford), which provides for an additional $325.0 million in gross proceeds, (i) $100.0 million of which was funded upon execution of the amendment and (ii) up to an additiona
- SECSEC Form 10-Q filed by Inhibrx Biosciences Inc.10-Q - Inhibrx Biosciences, Inc. (0002007919) (Filer)
- SECSEC Form SCHEDULE 13G filed by Inhibrx Biosciences Inc.SCHEDULE 13G - Inhibrx Biosciences, Inc. (0002007919) (Subject)
- SECInhibrx Biosciences Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Creation of a Direct Financial Obligation, Unregistered Sales of Equity Securities, Regulation FD Disclosure, Financial Statements and Exhibits8-K - Inhibrx Biosciences, Inc. (0002007919) (Filer)
- PRInhibrx Announces Amended Loan Agreement with Oxford Finance, Expanding Total Facility to $500.0 MillionSAN DIEGO, July 16, 2026 /PRNewswire/ -- Inhibrx Biosciences, Inc. ("Inhibrx" or the "Company") (NASDAQ:INBX), a clinical-stage biopharmaceutical company focused on developing novel biologic therapeutic candidates, today announced it entered into the Second Amendment (the "Second Amendment") to the Loan and Security Agreement, as amended (the "Amended LSA") with Oxford Finance LLC ("Oxford," together with certain of its affiliates party thereto, the "Lenders"), pursuant to which the Lenders expanded the facility to an aggregate principal amount of up to $500.0 million (the "Credit Facility"). The Second Amendment provides for a
- SECInhibrx Biosciences Inc. filed SEC Form 8-K: Regulation FD Disclosure, Other Events, Financial Statements and Exhibits8-K - Inhibrx Biosciences, Inc. (0002007919) (Filer)
- PRInhibrx Announces U.S. FDA Acceptance of BLA for Ozekibart in Patients with Conventional ChondrosarcomaNo filing review issues identified by FDA with PDUFA goal date set for April 14, 2027If Approved, Ozekibart Would Be the First and Only FDA-Approved Treatment for Unresectable or Metastatic Conventional Chondrosarcoma SAN DIEGO, June 15, 2026 /PRNewswire/ -- Inhibrx Biosciences, Inc. (NASDAQ:INBX) ("Inhibrx" or the "Company"), a clinical-stage biopharmaceutical company focused on developing novel biologic therapeutic candidates, today announced that the U.S. Food and Drug Administration (FDA) has accepted for filing its Biologics License Application (BLA) seeking approval of ozekibart (INBRX-109) for the treatment of patients with unresectable or metastatic conventional chondrosarcoma. The F
- INSIDERSEC Form 4 filed by Director Vuori Kristiina Md4 - Inhibrx Biosciences, Inc. (0002007919) (Issuer)
- INSIDERSEC Form 4 filed by Director Kayyem Jon Faiz4 - Inhibrx Biosciences, Inc. (0002007919) (Issuer)
- INSIDERSEC Form 4 filed by Director Forsyth Douglas4 - Inhibrx Biosciences, Inc. (0002007919) (Issuer)
- INSIDERSEC Form 4 filed by Director Manhard Kimberly4 - Inhibrx Biosciences, Inc. (0002007919) (Issuer)
- SECInhibrx Biosciences Inc. filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders8-K - Inhibrx Biosciences, Inc. (0002007919) (Filer)
- SECAmendment: SEC Form SCHEDULE 13G/A filed by Inhibrx Biosciences Inc.SCHEDULE 13G/A - Inhibrx Biosciences, Inc. (0002007919) (Subject)
- SECAmendment: SEC Form SCHEDULE 13G/A filed by Inhibrx Biosciences Inc.SCHEDULE 13G/A - Inhibrx Biosciences, Inc. (0002007919) (Subject)
- SECInhibrx Biosciences Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits8-K - Inhibrx Biosciences, Inc. (0002007919) (Filer)
- SECSEC Form 10-Q filed by Inhibrx Biosciences Inc.10-Q - Inhibrx Biosciences, Inc. (0002007919) (Filer)
- PRInhibrx Reports First Quarter 2026 Financial ResultsSAN DIEGO, May 14, 2026 /PRNewswire/ -- Inhibrx Biosciences, Inc. (NASDAQ:INBX) ("Inhibrx" or the "Company") today reported financial results for the first quarter of 2026. The biopharmaceutical company has two programs in ongoing clinical trials. Recent Corporate Highlights and Upcoming MilestonesINBRX-106In May 2026, we announced updated interim data from our randomized, first-line Phase 2 portion of the HexAgon study. The trial evaluated the safety and efficacy of INBRX-106, a hexavalent OX40 agonist, in combination with pembrolizumab (the combination arm) versus pembrolizuma
- SECInhibrx Biosciences Inc. filed SEC Form 8-K: Regulation FD Disclosure, Other Events, Financial Statements and Exhibits8-K - Inhibrx Biosciences, Inc. (0002007919) (Filer)
- PRInhibrx Reports Interim Phase 2 Data for INBRX-106 in First-Line HNSCC; Initial Results Demonstrate Potential Costimulatory Benefit Over PD-1 MonotherapyInterim analyses show INBRX-106 + pembrolizumab achieved a 44.0% confirmed Objective Response Rate (cORR): In the preliminary confirmed response-evaluable population, the INBRX-106 + pembrolizumab combination achieved a cORR of 44.0% versus 21.4% with pembrolizumab alone, representing a 22.6% absolute increase in cORR.Superior depth of response: Responding patients in the combination arm demonstrated deeper tumor reductions overall, with the majority achieving target lesion shrinkage exceeding 50%; notably, three patients achieved a complete radiographic response.Up to 15-fold mean increase in systemic T-Cell expansion: Peripheral blood analysis showed robust CD8+ and CD4+ T-cell proliferati
- PRInhibrx To Host Webcast Presentation to Provide Clinical Update on INBRX-106 HexAgon Study in First Line HNSCC– Event to be webcast live on Monday, May 11, 2026, at 5:30 a.m. PT –SAN DIEGO, May 8, 2026 /PRNewswire/ -- Inhibrx Biosciences, Inc. (NASDAQ:INBX) ("Inhibrx" or the "Company"), a clinical-stage biopharmaceutical company focused on developing therapeutics for oncology and rare diseases, today announced that it will host a live webcast presentation on Monday, May 11, 2026 at 5:30 a.m. Pacific Time to provide interim results from the randomized, first-line Phase 2 portion of the HexAgon study, which is evaluating the safety and efficacy of INBRX-106, a hexavalent OX40 agonist, in combination with pembrolizumab (the combination arm) versus pembrolizumab monotherapy (the control arm) in first-li
- INSIDERSEC Form 4 filed by President Matly David4 - Inhibrx Biosciences, Inc. (0002007919) (Issuer)
- SECSEC Form DEFA14A filed by Inhibrx Biosciences Inc.DEFA14A - Inhibrx Biosciences, Inc. (0002007919) (Filer)
INBX FAQ
6 questionsWhat does Inhibrx Biosciences Inc. do?
Inhibrx, Inc., a clinical-stage biotechnology company, focuses on developing a pipeline of novel biologic therapeutic candidates. Its therapeutic candidates include INBRX-109, a tetravalent agonist of death receptor 5, which is in Phase 1 clinical trials in patients with solid tumors, including sarcoma; and INBRX-105, an tetravalent conditional agonist of programmed death ligand 1 (PD-L1) and a conditional agonist of 4-1BB that is in Phase 1 clinical trials to treat patients with PD-L1 expressing tumors. The company's therapeutic candidates also comprise INBRX-101, an Fc fusion protein...Where does INBX stock trade?
Inhibrx Biosciences Inc. (INBX) is listed on NASDAQ.What sector and industry is INBX in?
Inhibrx Biosciences Inc. operates in the Health Care sector, Biotechnology: Biological Products (No Diagnostic Substances) industry.What are analysts saying about INBX?
Inhibrx Biosciences Inc. has had 8 recent analyst actions on file. The most recent action was from H.C. Wainwright: Buy on 2026-08-24. Recent price targets cluster around $4000.00.What companies are similar to INBX?
Notable peers in the same industry include AMGN (Amgen Inc.), GILD (Gilead Sciences Inc.), MRNA (Moderna Inc.), ARGX (argenx SE), RVMD (Revolution Medicines Inc.). Compare INBX side-by-side with any of them on Quantisnow.How can I track INBX on Quantisnow?
Quantisnow aggregates Inhibrx Biosciences Inc.'s SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow INBX to receive live email and push alerts on every new disclosure.